

MEDIA RELEASE
FOR IMMEDIATE RELEASE

**BIOACTIVX LAUNCHES HSA-APPROVED SYNTHETIC SKIN SUBSTITUTE
AND OPENS NEW SINGAPORE MANUFACTURING FACILITY**

Singapore MedTech company moves Bioactiv® Matrix from locally developed research into commercial production, supported by strategic partnerships for clinical adoption and international growth

SINGAPORE, 16 September 2026 – Bioactivx, a Singapore regenerative biomaterials company spun off from A*STAR and SingHealth, today announced the commercial launch of Bioactiv® Matrix, following its approval by Singapore's Health Sciences Authority (HSA).

The company also officially opened its new office and manufacturing facility at BLOCK71 and announced strategic collaborations to support clinical adoption, manufacturing innovation and international expansion.

The launch was officiated by Ms Tin Pei Ling, Member of Parliament for MacPherson, Marine Parade-Braddel Heights GRC and a member of the Government Parliamentary Committee for Finance, Trade and Industry.

Bioactiv® Matrix is a fully synthetic, bioactive skin substitute for second degree burn and deep abrasion wounds. It is designed to support tissue regeneration and faster wound closure while reducing inflammation and the risk of infection.

Unlike skin substitutes derived from animal collagen, Bioactiv® Matrix contains no animal-derived materials. Its synthetic composition supports scalable manufacturing and enables its use across culturally diverse patient populations and a range of clinical and operational environments.

From Singapore research to an approved medical product

Bioactiv® Matrix was developed through years of collaboration between scientists and clinicians in Singapore. Its HSA approval marks Bioactivx's transition from research and clinical development into commercialisation.

Preclinical studies demonstrated near full re-epithelialisation by day seven and no inflammation by day 15. Early clinical studies also showed faster wound closure compared with the current standard of care.

To date, the technology has undergone 6 preclinical studies and a first-in-human clinical study.

“Today represents a defining moment for Bioactivx,” said Dr Teo Peili, Co-founder and Chief Executive Officer of Bioactivx.

“Bioactiv® Matrix began with a scientific question: could we develop a fully synthetic material that supports the body’s natural healing process without relying on animal-derived materials, stem cells or growth factors?”

“HSA approval allows us to take an important step towards bringing this Singapore-developed innovation to clinicians and patients. Together with our new manufacturing capabilities and strategic partners, we now have the foundation to scale from Singapore and address unmet needs in burn and wound care internationally.”

Strengthening Singapore’s MedTech commercialisation capabilities

Bioactivx’s new facility at BLOCK71 brings together its corporate, research and manufacturing operations. It provides the company with the capacity to manufacture Bioactiv® Matrix in Singapore and support growing commercial demand.

The facility operates within Bioactivx’s ISO 13485-certified quality management system and incorporates advanced additive-manufacturing capabilities for the scalable production of its regenerative biomaterials.

Its opening follows Bioactivx’s US\$3 million Pre-Series A funding round, co-led by ContInvest and Cocoon Capital. The round brought the company’s total funding raised to US\$4.9 million.

The funding is being used to scale production, expand the company’s commercial capabilities, pursue regulatory approvals in international markets and advance its pipeline of synthetic regenerative products.

Partnerships to move from approval to adoption

During the event, Bioactivx formalised and highlighted collaborations with technology and commercial partners to support the adoption and international deployment of its regenerative solutions.

These include:

- UltiMaker – to explore how advanced additive manufacturing can support product development, manufacturing innovation and the rapid deployment of regenerative solutions in humanitarian and disaster-affected areas.

- NovaTech – to support the distribution and deployment of Bioactivx’s solutions in defence, field-care and operational environments.

Together, these collaborations provide pathways from regulatory approval to clinical adoption, professional training, distributed manufacturing and international market access.

“Regulatory approval is an essential milestone, but the real impact comes when an innovation reaches clinicians and patients,” Dr Teo said.

“Our partners bring the clinical expertise, manufacturing capabilities and market access needed to take Bioactiv® Matrix beyond the laboratory and into the settings where it can make a meaningful difference.”

Building a global synthetic regenerative medicine platform

Bioactiv® Matrix is the first commercial product developed from Bioactivx’s proprietary synthetic biomaterials platform.

Beyond burns and complex wounds, the company is developing a broader pipeline of regenerative solutions for wound care and bone defect repair in orthopaedics.

Bioactivx’s longer-term ambition is to establish a new class of synthetic regenerative products that can be manufactured at scale and deployed across hospitals, community healthcare facilities, military and field environments, and regions where conventional treatments may be difficult to access.

Following its commercial launch in Singapore, Bioactivx will focus on introducing Bioactiv® Matrix to clinicians locally while pursuing regulatory approvals, clinical partnerships and distribution opportunities in regional and international markets.

– END –

About Bioactivx

Bioactivx is a Singapore-based regenerative biomaterials company spun off from A*STAR and SingHealth. The company develops fully synthetic, second degree burn and deep abrasion wounds. It is designed to support faster wound closure while reducing inflammation and the risk of infection, without relying on animal- or human-derived materials.

Bioactivx's proprietary biomaterials platform is supported by a portfolio of 27 patent filings, including four granted patents. The company is developing regenerative solutions across wound care and orthopedics.

For more information, visit www.bioactivx.com.

Media Contact

Justin Fong

Head of Marketing

Bioactivx Pte Ltd

Mobile: +65 9732 0796

Email: Justin.Fong@bioactivx.com

Website: www.bioactivx.com

Enclosed:

ANNEX A – Product Sheet

ANNEX B – Company Fact Sheet

ANNEX C – Founders' Profiles

ANNEX A- PRODUCT SHEET

Problems associated with current second degree burn treatment

- 11M+ patients worldwide suffer from burn injuries annually (US > 500k annual burns, 40k hospitalised). ~ 70% burn injuries are second degree in nature.
- Mainly collagen-based dressings or decellularized pig skin
- Treatment must be administered in sterile environment within 24 hours of injury
- Resource intensive treatment required to minimize complications from infection



High Infection
Risks



> 10 days
Inpatient



Permanent
Scarring


First in Class: Synthetic 3D Printed Bioactiv[®] Matrix

- Biomaterial platform technology for tissue regeneration using synthetic materials
- Bioactiv Matrix is our flagship product for treatment of skin wounds
- Scalable 3D Printing technology for high porosity to facilitate wound fluid transmission and reduce material wastage
- The Bioactiv[®] Matrix is designed to rapidly **stimulate tissue regeneration and fast wound healing, thereby leading to significantly improved clinical outcomes and patient's quality of life.**



Value Proposition

- 2x faster healing
 - ⇒ Improving patient quality of life
 - ⇒ Quicker bed turnover rate for hospitals and lower treatment costs for patients
- Synthetic nature
 - ⇒ More bacteria averse than incumbents
 - ⇒ Reduced complication/ infection rate
 - ⇒ Works in non-sterile settings; ideal for field and military use
- Cost effective
 - ⇒ Scalable production design for economies of scale
 - ⇒ Reduced storage/ usage costs for hospitals
 - ⇒ Affordable alternative for patients
- Religiously inclusive
 - ⇒ Synthetic nature allows for market entry into Muslim or Hindu majority countries



Bioactiv® Matrix – Revolutionary burn treatment

- Two times faster wound healing in patients treated with Bioactiv® Matrix compared to patients treated with standard of care.
- Scar-free healing in most patients
- Patients are not affected by bacteria infection
- Early discharge for patients





Competitor Analysis of Skin Substitutes for Burns

Commonly used skin substitutes					
					
Product name	Bioactiv Matrix	Biobrane	Integra wound matrix	Suprathel	Kerecis
Culturally agnostic	✓	X	X	✓	X
Bioactivity	✓	✓	✓	X	✓
Can be stored without cold chain requirement	✓	X	X	X	X
No skin staples or suture needed	✓	X	X	X	X

ANNEX B- COMPANY FACT SHEET

Company Name: Bioactivx Pte Ltd

Headquarters: Singapore

Founded: 2023

Stage: Pre-Series A Round (Funded 2026)

Website: www.bioactivx.com

Contact: enquiries@bioactivx.com | investors@bioactivx.com

Our Mission & Vision

To redefine tissue repair by developing **synthetic, bioinspired regenerative materials** that deliver faster healing, lower infection risk and inflammation reduction (or anti-inflammatory) without relying on animal-derived products, auto/allografts, stem cells or growth factors.

Our **Vision** is to become a **global leader in synthetic regenerative medicine**, transforming how skin, bone, and cartilage are repaired making faster, safer healing accessible to all.

Our Technology

Bioactivx's patented **Bioactiv® Materials Platform** integrates **bioactive synthetic polymers** that can induce tissue regeneration, reduce inflammation and/ or antimicrobial with engineering processes, to manufacture clinically useful medical implants to treat various diseases.

- **Wholly synthetic and acellular:** zero animal components, shelf-stable at room or elevated summer temperatures.
- **Clinically validated:** faster wound closure and reduced inflammation in first-in-human trials.
- **Scalable platform:** applicable across wound care, orthopedics, and cartilage regeneration.

Flagship Product — Bioactiv® Matrix

A synthetic skin substitute that reduces wound healing time in second degree burn injuries by half, outperforming current standard of care.

Our Product Pipeline

Product	Indication	Stage	Next Milestone
Bioactiv™ Matrix	Partial-thickness burns, chronic wounds	Completed FIH	Regulatory submission (2026)
Bioactiv™ Foam	Acute & chronic wounds	Pre-clinical completed	Clinical trial (2026)
Bioactiv™ Cellulose	Chronic ulcers / diabetic foot ulcers	Preclinical ongoing	Complete preclinical validation (2027)
Bioactiv Bone graft	Bone trauma fixation	Completed preclinical	Clinical trial 2026
Bioactiv plug	Cartilage repair in ankle joints	Preclinical ongoing	Complete product design and validation (2028)

Scientific & Clinical Validation

- **17 pre-clinical trials** completed
- **11-patient FIH** with superior healing vs standard of care
- **27 patents filed, 4 granted globally**
- **7 peer-reviewed publications**, including *ACS Materials Au* (2023) and *Polym. Chem.* (2023)
- Collaborations with **A*STAR, SingHealth** and **Mitsui Chemicals**.

Market Impact

The global **advanced wound-care market** is projected to exceed **US \$25 billion by 2030**, driven by rising demand for safer, faster, and non-animal solutions.

Bioactivx is uniquely positioned to meet this need through its **wholly synthetic and culturally agnostic platform**, serving over **3 billion patients** worldwide with religious or cultural restrictions against porcine- or bovine-derived materials.

Beyond cultural inclusivity, **Bioactiv® Matrix** eliminates the need for **cold-chain logistics or sterile-only environments**. Unlike collagen-based or cell-based wound dressings that must be refrigerated and applied in controlled settings, Bioactivx's materials are **shelf-stable at room temperature** and can be used **in field hospitals, rural clinics, and humanitarian or military missions**. This enables **true portability of advanced burn and wound care** extending modern regenerative medicine to places where conventional biologics cannot reach. By removing these logistical and cultural barriers, Bioactivx is **democratizing access to healing** worldwide.

Founding Team

- **Dr Peili Teo**, Co-founder and Chief Executive Officer. A*STAR Principal Scientist | Adj. Senior Lecturer (NUS), Postdoc under Nobel Laureate Professor Robert H. Grubbs (California Institute of Technology, Caltech)
- **Dr Woo Yew Lok**, Co-Founder & Clinical Advisor. Consultant Orthopaedic Surgeon, SGH | Duke-NUS Clinical Professor

ANNEX C – FOUNDERS’ PROFILES

Dr Peili Teo, Co-founder & Chief Executive Officer

Dr Peili Teo leads the scientific vision and technology strategy at Bioactivx, where she pioneers the design of next-generation synthetic biomaterials for tissue regeneration. With more than 20 years of experience spanning chemistry, polymer science, and translational medicine, she bridges academic excellence with clinical relevance.



An A*STAR Scholar from 2004 to 2011, Dr Teo completed her PhD in Chemistry at the National University of Singapore and a postdoctoral fellowship under Nobel Laureate Prof Robert H. Grubbs at the California Institute of Technology. She later became an A*STAR Principal Scientist at the Institute of Materials Research & Engineering. She is also an alumnus of Singapore Biodesign Innovation Fellowship.

Her innovations in bioactive synthetic polymers - a biomaterial platform that enables the synthesis of functional biomolecule-linked polymers such as patented PLGA-, PCL- and PE-biomolecules - have yielded multiple wound-care and orthopedic devices demonstrating superior healing outcomes in pre-clinical and first-in-human studies. Dr Teo has authored over 25 peer-reviewed publications, filed 27 patents (four granted), and secured multi-million-dollar research grants from A*STAR, NHIC and NRF.

At Bioactivx, she drives the company’s R&D roadmap across skin, bone and cartilage regeneration, ensuring scientific rigor, regulatory readiness, and global IP protection.

Dr Woo Yew Lok, Co-founder

Dr Woo Yew Lok is a **Consultant Orthopedic Surgeon** at the **Singapore General Hospital** and a **Clinical Assistant Professor at Duke-NUS Medical School**. His subspecialty expertise covers **joint reconstruction, trauma and cartilage repair**, and he serves as **Honorary Treasurer of the Asia Pacific Orthopaedic Fragility Fracture Society**.



Dr Woo earned his medical degree from **Universiti Kebangsaan Malaysia**, his **Master of Medicine (Ortho)** from NUS, and is a **Fellow of the Royal College of Surgeons of Edinburgh**. He has authored 10+ publications in peer-reviewed journals and contributes actively to orthopedic education through AO Trauma and national residency programs. Dr Woo is also an active researcher, codeveloping next generation synthetic tissue regenerative

bone substitutes with Dr Teo.

At Bioactivx, Dr Woo provides **clinical insight and validation** for the company's orthopedic and cartilage-repair programs, ensuring translational alignment from bench to bedside.